novo nordisk wegovy - Search News

News

Novo Nordisk ousts CEO

CNBC on MSN · 1d

Novo Nordisk is betting on a CEO shakeup to regain its weight loss drug edge over Eli Lilly

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and navigate other challenges

Associated Press News on MSN · 4d

CEO of Novo Nordisk, maker of weight loss drug Wegovy, to step down in wake of share price drop

Pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, says its CEO is stepping down.

Insider Monkey on MSN · 10h

Novo Nordisk Places Bet on CEO Shake-Up to Reclaim Edge in Weight Loss Drug Race

As its obesity medication Wegovy loses a sizable portion of the market to Eli Lilly and Company (NYSE:LLY)’s competing medicine, Zepbound, the Danish pharmaceutical behemoth Novo Nordisk A/S (NYSE:NVO) abruptly announced the resignation of veteran CEO Lars Fruergaard Jørgensenm last week.

11hon MSN

Why Novo Nordisk Stock Popped on Tuesday

Novo Nordisk ( NVO 1.82%) stock jumped 3% through 10:55 a.m. Tuesday on some potentially positive news in the GLP-1 weight ...

30m

Novo Nordisk joins finance’s great one-hit wonders

In the near term, commercial efforts might raise the chances that new patients are prescribed Novo Nordisk’s drug, assuming ...

13hon MSN

Weight-loss company Noom pivots to smaller doses of compounded Wegovy

Online weight-loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy as the U.S.

Axios on MSN4d

Wegovy maker Novo Nordisk CEO to step down

Novo Nordisk CEO Lars Fruergaard Jørgensen is stepping down as the Danish drug giant faces increased competition for its ...

5d

Ignore The Noise - Novo Nordisk Is A Clear Buy

Novo Nordisk's current product portfolio is well-protected by patents until at least 2030. Click here to see why NVO stock is ...

13don MSN

Novo Nordisk hopes to see US Wegovy sales recover soon

Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the United States to start to recover once a ban on compound ...

6don MSN

This biotech’s stock rockets on oral obesity-drug partnership with Wegovy parent

Wednesday trading after the biotech clinched a partnership with Wegovy and Ozempic parent Novo Nordisk to collaborate on oral ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results